MaxCyte, Inc.
$0.86
▲
0.74%
2026-04-21 08:18:01
www.maxcyte.com
NMS: MXCT
Explore MaxCyte, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$91.86 M
Current Price
$0.86
52W High / Low
$2.96 / $0.64
Stock P/E
—
Book Value
$1.61
Dividend Yield
—
ROCE
-24.06%
ROE
-23.63%
Face Value
—
EPS
$-0.42
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
91
Beta
1.45
Debt / Equity
10.46
Current Ratio
8.3
Quick Ratio
7.77
Forward P/E
-2.94
Price / Sales
2.56
Enterprise Value
$-0.53 M
EV / EBITDA
0.01
EV / Revenue
-0.02
Rating
Buy
Target Price
$4.05
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Xtant Medical Holdings, Inc. | $0.5 | 15.1 | $75.1 M | — | 11.26% | 10.59% | $0.95 / $0.39 | $0.36 |
| 2. | Alphatec Holdings, Inc. | $11.55 | — | $1.68 B | — | -10.13% | -6.31% | $23.29 / $9.89 | $0.08 |
| 3. | AVITA Medical, Inc. | $5 | — | $157.45 M | — | 676.75% | 799.72% | $10.29 / $3.22 | $-0.55 |
| 4. | Beta Bionics, Inc. | $12.91 | — | $576.08 M | — | -24.07% | -40.26% | $32.71 / $8.8 | $6.48 |
| 5. | UFP Technologies, Inc. | $201.08 | 22.53 | $1.54 B | — | 16.02% | 17.82% | $274.93 / $182.87 | $54.95 |
| 6. | Accuray Incorporated | $0.46 | — | $52.79 M | — | 2.82% | -70.32% | $2.1 / $0.33 | $0.45 |
| 7. | SS Innovations International, Inc. | $4.85 | — | $971.12 M | — | -17.08% | -46.94% | $22.42 / $3.02 | $0.2 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 7.3 M | 6.83 M | 8.51 M | 10.39 M | 8.69 M | — |
| Operating Profit | -7.67 M | -11.09 M | -14.23 M | -12.29 M | -12.9 M | — |
| Net Profit | -9.6 M | -12.42 M | -12.36 M | -10.26 M | -10.6 M | — |
| EPS in Rs | -0.09 | -0.12 | -0.12 | -0.1 | -0.1 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 33.03 M | 38.63 M | 41.29 M | 44.26 M |
| Operating Profit | -45.28 M | -51.2 M | -48.3 M | -27.36 M |
| Net Profit | -44.63 M | -41.05 M | -37.92 M | -23.57 M |
| EPS in Rs | -0.42 | -0.38 | -0.35 | -0.22 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 202.51 M | 239.47 M | 268.27 M | 286.65 M |
| Total Liabilities | 31.02 M | 33.22 M | 36.11 M | 32.69 M |
| Equity | 171.49 M | 206.25 M | 232.17 M | 253.97 M |
| Current Assets | 118.37 M | 171.68 M | 190.19 M | 252.27 M |
| Current Liabilities | 14.27 M | 15.78 M | 17.86 M | 15.43 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -34.41 M | -27.61 M | -21.69 M | -14.78 M |
| Investing CF | 25.93 M | 6.93 M | 54.98 M | -24.82 M |
| Financing CF | 0.66 M | 2.06 M | 2.14 M | 2.89 M |
| Free CF | -36.18 M | -29.26 M | -25.39 M | -33.26 M |
| Capex | -1.77 M | -1.65 M | -3.7 M | -18.48 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -6.44% | -6.72% | — | — |
| Earnings Growth % | -8.26% | -60.89% | — | — |
| Profit Margin % | -106.29% | -91.85% | -53.25% | — |
| Operating Margin % | -132.54% | -116.98% | -61.82% | — |
| Gross Margin % | 81.62% | 88.51% | 88.48% | — |
| EBITDA Margin % | -120.14% | -105.92% | -55.72% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.